The Cerebrospinal System Failure Score (CSF-Score): A Multidimensional Prognostic Tool for Leptomeningeal Metastasis from Non-Small Cell Lung Cancer
Clicks: 5
ID: 324859
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
1.2
/100
5 views
4 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #2 of 43 articles by views in Neuro-Oncology Practice
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract BACKGROUND Leptomeningeal metastasis (LM) from non-small cell lung cancer (NSCLC) has entered a new therapeutic era, yet no validated composite prognostic score jointly captures functional, molecular, anatomical, and cerebrospinal fluid (CSF) dynamic dimensions. We developed and internally validated the Cerebrospinal System Failure Score (CSF-Score), a pre-specified five-dimensional prognostic score for NSCLC-LM. METHODS We retrospectively analyzed 123 consecutive patients with cytology-confirmed NSCLC-LM between January 2022 and June 2025. The CSF-Score (0–10 points) was constructed a priori and integrates host resilience, molecular engine, anatomical burden, fluid dynamics, and biological toxicity, with a Karnofsky Performance Status <60 gatekeeper directing patients to the high-risk stratum. Patients were classified as low- (0–2), intermediate- (3–6), or high-risk (≥7 or gatekeeper). Discrimination was assessed using Harrell’s C-index with 1,000-resample bootstrap internal validation and temporal split validation. RESULTS Median OS was 20.5 months (95% CI 16.6–23.9), 12.6 months (95% CI 8.9–15.8), and 4.5 months (95% CI 3.2–5.7) in the low- (n = 32), intermediate- (n = 49), and high-risk (n = 42) groups, respectively (log-rank p < 0.001). The C-index was 0.741 (95% CI 0.705–0.779), with negligible optimism after bootstrap correction and stable temporal split validation (training 0.742 vs testing 0.733). Four of five dimensions retained independent significance on multivariable analysis; fluid dynamics showed a mediation-consistent attenuation pattern. The total score remained independently associated with OS after adjustment for treatment covariates (HR 1.28 per point, p < 0.001). CONCLUSIONS The pre-specified CSF-Score achieved clear three-tier prognostic stratification in NSCLC-LM while incorporating dimensions relevant to CSF system status. External multicenter validation is required before clinical adoption.
| Reference Key |
openalex_W7202384115
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Haoxiang Xu, Chengyin Lu, Haotian Shen, Chao Ma, Dairan Zhou, Xiaomin Niu, Xiaodong Jiao, Di Zheng, Mianshun Pan, Liyan Jiang, Lijun Hou, Tao Xu |
| Journal | Neuro-Oncology Practice |
| Year | 2026 |
| DOI |
10.1093/nop/npag085
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.